Coregulator-related diseases

Internal Medicine

Volumn 43, Issue 5, 2004, Pages 368-373

  Yanase, Toshihiko ^a   Adachi, Masahiro ^a   Goto, Kiminobu ^a   Takayanagi, Ryoichi ^a   Nawata, Hajime ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Androgen insensitivity syndrome (AIS); Coactivator; Coregulator; Corepressor; Hormone dependent cancer; Leukemia; Refetoff syndrome; Rubinstein Tabi syndrome

Indexed keywords

BRCA1 PROTEIN; CELL NUCLEUS RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN E; DNA BINDING PROTEIN; PROTEIN TYROSINE KINASE; RNA POLYMERASE II; STEROID RECEPTOR;

ANDROGEN INSENSITIVITY SYNDROME; CARCINOGENESIS; DEMENTIA; DNA BINDING; FEMINIZATION; GENE MUTATION; HORMONE RESISTANCE; HUMAN; HYPOTHYROIDISM; MALE INFERTILITY; ONCOGENE; REVIEW; RUBINSTEIN SYNDROME; THYROID HORMONE RESISTANCE; VIRILIZATION; X CHROMOSOME LINKED DISORDER;

ANDROGEN-INSENSITIVITY SYNDROME; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; RECEPTORS, ANDROGEN; RUBINSTEIN-TAYBI SYNDROME; SENSITIVITY AND SPECIFICITY; THYROID HORMONE RESISTANCE SYNDROME; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS;

EID: 3042652971     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.368     Document Type: Review

References (32)

1. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 83: 835-839, 1995.
2. Horwitz KB, Jackson TA, Bain DL, Takimoto GS, Tung L. Neclear receptor coactivators and corepressors. Mol Endocrinol 10: 1167-1177, 1996.
3. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20: 321-344, 1999.
4. Chrousos GP. A new "new" sundrome in the new world: is multiple postreceptor steroid hormone resistance due to a coregulator defect? J Clin Endocrinol Metab 84: 4450-4453, 1999.
5. Adachi M, Takayanagi R, Tomura A, et al. Androgen-insensitivity syndrome as a possible coactivator disease. N Engl J Med 343: 856-862, 2000 (Errantum in: N Engl J Med 344: 696).
6. Petrij F, Giles RH, Dauwerse HG, et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376: 348-351, 1995.
7. Ito M, Roeder RG. TheTRAP/SMCC/Mediator complex and thyrpid hormone receptor function. Trends in Endocrinol & Metababolism 12: 127-134, 2001.
8. Zhao Y, Goto K, Saitoh M, et al. Activation function-1 domain of androgen receptor contributes to the interaction between subnuclear splicing factor compartment and nuclear receptor compartment; Identification of the p102 U5 snRNP binding protein as a coactivator for the receptor. J Biol Chem 277: 30031-30039, 2002.
9. Saitoh M, Takayanagi R, Goto K, et al. The presence of the amino- and carboxy-terminal domains in androgen receptor is essential for the completion of a transcriptionally active form with coactivators and intranuclear compartmentalization common to the steroid hormone receptors: A three-dimensional imaging study. Mol Endocrinol 16: 694-706, 2002.
10. Quigley CA, De Bellis A, Marschke KB, el Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 16; 271-321, 1995.
11. Ahmed SF, Cheng A, Dovey L, et al. Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome. J Clin Endocrinol Metab 85: 658-665, 2000.
12. Rubinstein JH, Taybi H. Broad thumbs and toes and facial abnormalities. Am J Dis Child 105: 588-608, 1963.
13. Kamei Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85: 403-414, 1996.
14. Tanaka Y, Naruse I, Maekawa T, Masuya H, Shiroishi T, Ishii S. Abnormal skeletal patterning in embryos lacking a single Cbp allele: a partial similarity with Rubinstein-Taybi syndrome. Proc Natl Acad Sci USA 94: 10215-10220, 1997.
15. Yao TP, Oh SP, Fuchs M, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional interator p300. Cell 93: 361-372, 1998.
16. Oike Y, Hata A, Mamiya T, et al. Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Hum Mol Genet 8: 387-396, 1999.
17. Murata T, Kurokawa R, Krones A, et al. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein Taybi syndrome. Hum Mol Genet 10: 1071-1076, 2001.
18. Petrij F, Dauwerse HG, Blough RI, et al. Diagnostic analysis of the Rubinstein-Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations. J Med Genet 37: 168-176, 2000.
19. New MI, Nimkarn S, Brandon DD, et al. Resistance to several steroids in two sisters. J Clin Endocrinol Metab 84: 4454-4464, 1999.
20. New MI, Nimkarn S, Brandon DD, et al. Resistance to multiple steroids in two sisters. J Steroid Biochem Mol Biol 76: 161-166, 2001.
21. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279: 1921-1925, 1998.
22. Safer JD, Cohen RN, Hollenberg AN, Wondisford EF. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone. J Biol Chem 273: 30175-30182, 1998.
23. Yoh SM, Chatterjee VK, Privalsky ML. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors. Mol Endocrinol 11: 470-480, 1997.
24. Weiss RE, Xu J, Ning G, Pohlenz J, O'Maleey BW, Refetoff S. Mice deficient in the steroid receptor coactivator 1 (SRC-1) are resistant to thyroid hormone. EMBO J 18: 1900-1904, 1997.
25. Ito M, Yuan C-X, Okano HJ, Darnell RB, Roder RG. Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyrpod hormone action. Molecular Cell 5: 683-693, 2000.
26. Philibert RA, King BH, Winfield S, Cook EH, et al. Association of X-chromosome dedecamer insertional variant allele with mental retardation. Mol Psychiatry 3: 303-309, 1998 (Errantum in: Mol Psychiatry 4: 197, 1999).
27. Bautista S, Valles H, Walker RL, et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 4: 2925-2929, 1998.
28. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494, 1995.
29. Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20: 5041-5047, 2000.
30. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 12: 3488-3498, 1998.
31. Planas-Silva MD, Shang Y, Donaher JL, Brown M, Weinberg RA. AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res 61: 3858-3862, 2001.
32. Lutterbach B, Westendorf JJ, Linggi B, et al. ETO, a target of t (8; 21) inn acute leukemia, interacts with the NCoR amd mSin3 corepressors. Mol Cell Biol 18: 7176-7184, 1998.